Biotech

Functional Technologies Renews Agreement with Momentum Public Relations

VANCOUVER, BRITISH COLUMBIA: ...

Threshold Pharmaceuticals Announces Agreement With U.S. FDA on a Special Protocol Assessment for Planned Phase 3 Trial of TH-302 in Combination With Gemcitabine in Advanced Pancreatic Cancer

SOUTH SAN FRANCISCO, CA: ...

ProMetic Enters Into Commercial and Strategic Investment Agreements Totalling $21 Million with Shenzhen Hepalink Pharmaceutical Co., Ltd

LAVAL, QUEBEC, CANADA: - Agreements accelerate ProMetic's expansion strategy into Asian markets - $11 million commercial agreement includes an initial $2 million upfront payment and $9 million in milestones - Hepalink ...

The Medicines Company to Announce Third Quarter 2012 Financial Results on Wednesday, October 24, 2012

PARSIPPANY, NJ: Conference Call to Be Held at 8:30 a.m. Eastern Time ...

Corcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors

MENLO PARK, CA: ...

Genetic Technologies Files Patent Infringement Suits Against Multiple Alleged Infringers in USA

MELBOURNE, AUSTRALIA: ...

Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 17th Annual International World Muscle Society

CAMBRIDGE, MA: Previously Reported Data Demonstrated Study Met Primary Endpoint and Achieved Significant Clinical Benefit on 6-Minute Walk Test ...

Genome Canada Board Appoints New Chair

OTTAWA, ONTARIO: ...

Theratechnologies Announces Financial Results for Third Quarter of 2012

MONTREAL, CANADA: ...

Biotech Industry Looks to Benefit From New Act Designed to Promote R&D Joint Ventures

NEW YORK, NY: Five Star Equities Provides Stock Research on Array Biopharma and Zalicus ...